Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Strathe

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Research Synthesis Methods|June 2, 2026
Model-based network meta-analysis: Joint estimation of dose-response and time-course relationshipsAnders Strathe, Martin Bøg, Anders Gorst-Rasmussen
Diabetes, Obesity & Metabolism|February 4, 2020
Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approachTheodoros Papathanasiou, Anders Strathe, Henrik Agersø, et al.
Advances in Therapy|February 20, 2026
Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or ObesityKristine Færch, Mikel M Gomes, Maja Bramming, et al.
The AAPS Journal|July 31, 2019
Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response ModelsTheodoros Papathanasiou, Anders Strathe, Rune Viig Overgaard, et al.
The AAPS Journal|April 25, 2018
Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug CombinationsTheodoros Papathanasiou, Anders Strathe, Andrew C Hooker, et al.
Diabetes, Obesity & Metabolism|April 23, 2026
Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development ApproachRune Viig Overgaard, Oscar Birkhan, Naveen Rathor, et al.
Diabetes, Obesity & Metabolism|March 30, 2026
Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development ApproachAnders Strathe, Eric M Bomberg, Garrit Jensch, et al.
Diabetes, Obesity & Metabolism|July 10, 2023
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesityAnders Strathe, Deborah B Horn, Malte Selch Larsen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Research Synthesis Methods|June 2, 2026
Model-based network meta-analysis: Joint estimation of dose-response and time-course relationshipsAnders Strathe, Martin Bøg, Anders Gorst-Rasmussen
Diabetes, Obesity & Metabolism|February 4, 2020
Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approachTheodoros Papathanasiou, Anders Strathe, Henrik Agersø, et al.
Advances in Therapy|February 20, 2026
Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or ObesityKristine Færch, Mikel M Gomes, Maja Bramming, et al.
The AAPS Journal|July 31, 2019
Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response ModelsTheodoros Papathanasiou, Anders Strathe, Rune Viig Overgaard, et al.
The AAPS Journal|April 25, 2018
Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug CombinationsTheodoros Papathanasiou, Anders Strathe, Andrew C Hooker, et al.
Diabetes, Obesity & Metabolism|April 23, 2026
Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development ApproachRune Viig Overgaard, Oscar Birkhan, Naveen Rathor, et al.
Diabetes, Obesity & Metabolism|March 30, 2026
Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development ApproachAnders Strathe, Eric M Bomberg, Garrit Jensch, et al.
Diabetes, Obesity & Metabolism|July 10, 2023
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesityAnders Strathe, Deborah B Horn, Malte Selch Larsen, et al.
Pageof 1